Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukaemia

Trial Profile

Phase II Study of the Hyper - CVAD Regimen in Combination With Ofatumumab as Frontline Therapy for Patients With CD-20 Positive Acute Lymphoblastic Leukaemia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Feb 2018

At a glance

  • Drugs Ofatumumab (Primary) ; Cyclophosphamide; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Doxorubicin; Methotrexate; Methotrexate; Vincristine
  • Indications Burkitt's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 09 Feb 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2020.
    • 12 Dec 2017 Updated results (n=68) assessing the safety and efficacy of combination of Ofatumumab with Hyper-CVAD in adults with newly diagnosed acute lymphoblastic leukemia, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
    • 06 Jun 2017 Interim results (n=63) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top